Author

P. N. Gollavilli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

P. Ceppi· 4 shared A. Schwab· 3 shared V. Ramesh· 3 shared B. Parma· 2 shared I. A. Asangani· 2 shared L. Pinna· 2 shared M. A. Siddiqui· 2 shared M. E. Vazakidou· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

P. Ceppi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Propionate reinforces epithelial identity and reduces aggressiveness of non-small cell lung carcinoma via chromatin remodelling

V. Ramesh, P. N. Gollavilli, L. Pinna, M. A. Siddiqui, S. T. Jakobsen, E. L. Boiteux, K. E. Olsen, O. N. Jensen, R. Siersbaek, K. Somyajit, P. Ceppi

This study identifies propionate's role in reducing NSCLC aggressiveness by promoting epithelial identity through chromatin remodeling.

bioRxiv · Jan 19, 2023Cancer Biology

Metabolic breakdown of non-small cell lung cancers by mitochondrial HSPD1 targeting

B. Parma, V. Ramesh, P. N. Gollavilli, A. M. Siddiqui, L. Pinna, A. Schwab, S. Marshall, S. Zhang, C. Pilarsky, F. Napoli, M. Volante, S. Urbanczyk, D. Mielenz, H. D. Schroeder, M. Stemmler, , P. Ceppi

This study identifies HSPD1 as a therapeutic target in NSCLC, showing its disruption leads to metabolic breakdown and suppressed tumor growth.

bioRxiv · Mar 9, 2021Cancer Biology

Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer

M. A. Siddiqui, P. N. Gollavilli, V. Ramesh, B. Parma, A. Schwab, M. E. Vazakidou, R. Natesan, O. Saatci, I. Rapa, P. Bironzo, H. Schuhwerk, I. A. Asangani, O. Sahin, M. Volante, P. Ceppi

This study identifies thymidylate synthase (TS) as a driver of epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC), linking it to metastasis, chemotherapy resistance, and survival.

bioRxiv · Aug 13, 2020Cancer Biology

Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers

A. Siddiqui, P. N. Gollavilli, A. Schwab, M. E. Vazakidou, P. Ersan, M. Ramakrishnan, D. Pluim, S. A. Coggins, O. Saatci, L. Annaratone, J. H. Schellens, B. Kim, I. A. Asangani, S. A. K. Rasheed, C. Marchio, , P. Ceppi

This study shows that thymidylate synthase promotes de-differentiation in aggressive breast cancers by supporting pyrimidine catabolism and EMT, correlating with poor prognosis.

Cell Death & Differentiation · Nov 1, 2019Peer-reviewedCancer Biology